TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

RIMACTANE

RIFAMPIN
Infectious Disease Approved 1971-05-21
3
Indications
--
Phase 3 Trials
54
Years on Market

Details

Status
Prescription
First Approved
1971-05-21
Routes
ORAL
Dosage Forms
CAPSULE

Companies

Active Ingredient: RIFAMPIN

RIMACTANE Approval History

Loading approval history...

What RIMACTANE Treats

1 indications

RIMACTANE is approved for 1 conditions since its original approval in 1971. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Tuberculosis
Source: FDA Label
πŸ”¬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
πŸ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

RIMACTANE FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

In the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. Bacteriologic cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to rifampin and they should be repeated throughout therapy to monitor the response to treatment. Since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. If test results show resis...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.